XOMA to Announce Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call Focused on its New Strategic Direction on March 16, 2017
BERKELEY, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today it will issue its fourth quarter and full year 2016 financial results before the market opens on Thursday, March 16, 2017. In conjunction, the Company will host a conference call at 9:00 a.m. ET on Thursday, March 16, 2017, to review its business highlights and describe XOMA’s new strategic direction and initiatives.
The webcast can be accessed via the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay. An accompanying slide presentation also can be accessed via the XOMA website. Telephone numbers for the live conference call are 1-877-369-6589 (U.S./Canada) and 1-408-337-0122 (international) with the passcode 82058103.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.
CONTACTS: Investor contact: Luke Heagle Pure Communications +1 910-726-1372 firstname.lastname@example.org Media contact: Colin Sanford Pure Communications +1 415-946-1094 email@example.com
Released March 14, 2017